FIGURE 4 from An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers

<p>ENI10 predict pan-cancer survival independently of the cell cycle and more efficiently than other SC–derived signatures. <b>A,</b> ssGSEA score of the ENI10 signature in all tumors and normal samples from TCGA database. <b>B,</b> Correlation of CD10 signature score and survival in TCGA's Pan-Cancer Atlas. All tumor samples were pooled and the effect of the CD10-signature score discretized by deciles on survival outcome was evaluated from Cox models stratified on cancer types, using unadjusted (black marks), adjusted on age alone (blue marks, modeled with a 3-degree polynomial spline) or with a supplemental stratification term for stage (I/II/III/IV; green marks) or grade (1/2/3/4; red marks) pathologic scoring systems. Dots show the HR for PFI and adjacent bars the 95% confidence interval. <b>C,</b> Left: Overall Pan-Cancer analysis of the correlation between the ENI10 score and survival in TCGA's Pan-Cancer Atlas. All tumor samples were pooled and the effect of the ENI10 score discretized by deciles on survival outcome was evaluated from Cox models stratified on cancer types. Right: Same analysis with a reduced ENI10 signature were genes known to be regulated during the cell cycle were removed. <b>D</b> and <b>E,</b> Overall Pan-Cancer analysis of the effect of CD10 score on survival in TCGA's Pan-Cancer atlas. All tumor samples were pooled and the effect of the CD10 enrichment score discretized by deciles on survival outcome was evaluated using a multivariable Cox model including as covariables both the CD10 score and the Smith and colleagues (D) or Pece and colleagues (E) signatures<i>.</i> Dots show the hazard ratio for PFI and adjacent bars the 95% confidence interval.</p>